Dr. Liangjun Zhu 朱梁军
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and medical treatment of malignant tumors, with a focus on digestive tract cancers. Specializes in multidisciplinary care for advanced colorectal, gastric, and liver cancers, including biological targeted therapy and immunotherapy.
Dr. Zhu is a Chief Physician in the Department of Medical Oncology at Jiangsu Cancer Hospital. Dr. Zhu serves on expert committees for the Chinese Society of Clinical Oncology (CSCO) regarding colorectal cancer, liver cancer, and clinical research. Additional roles include positions with the Jiangsu Cancer Prevention and Control Alliance and the Jiangsu Medical Association.
Professional roles
- Standing Committee Member, Digestive Tract Tumor Multidisciplinary (MDT) Branch, China International Exchange and Promotion Association for Medical and Healthcare
- Member, Internal Medicine Treatment Professional Committee, Colorectal Tumor Professional Committee, Chinese Medical Doctor Association
- Member, Colorectal Cancer Branch of Abdominal Tumor, China Medicine Education Association
- Editorial Board Member, Annals of Oncology (Chinese Edition)
Name order: in Chinese the family name comes first (Zhu Liangjun). Papers usually list the name as Liangjun Zhu or Zhu L.
Selected publications
29 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2025 (senior author): Efficacy and safety of fruquintinib combined with immunotherapy in later-line treatment of metastatic colorectal cancer. PubMed 41050776
- Signal Transduct Target Ther, 2024 (senior author): Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial. PubMed 39658608
- Cancer Control, 2024 (senior author): Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial. PubMed 39286935
- EClinicalMedicine, 2023 (senior author): Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. PubMed 38024480
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion